tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of David Amsellem, 244 are a BUY (73.49%), 77 are a HOLD (23.19%), 11 are a SELL (3.31%).
Analyst David Amsellem, currently employed at PIPER SANDLER, carries an average stock price target met ratio of 53.86% that have a potential upside of 25.82% achieved within 204 days.
David Amsellem’s has documented 672 price targets and ratings displayed on 37 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on NBIX, Neurocrine Biosciences at 29-Aug-2024.
Analyst best performing recommendations are on RVNC (REVANCE THE).
The best stock recommendation documented was for RVNC (REVANCE THE) at 8/9/2024. The price target of $6 was fulfilled within 3 days with a profit of $2.47 (69.97%) receiving and performance score of 233.24.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Hold
2 years 9 months 14 days ago
0/1 (0%)
$34.88 (99.32%)
Hold
14
2 years 10 months 18 days ago
3/7 (42.86%)
$9.25 (194.74%)
87
Hold
7
$-1.22 (-14.84%)
7
2 years 10 months 19 days ago
3/8 (37.5%)
$-1.08 (-13.37%)
124
Buy
9.1
$0.88 (10.71%)
12
2 years 10 months 19 days ago
0/7 (0%)
$1.02 (12.62%)
Buy
6
$-2.22 (-27.01%)
20
2 years 10 months 19 days ago
0/2 (0%)
$3.2 (23.94%)
Which stock is David Amsellem is most bullish on?
Which stock is David Amsellem is most reserved on?
What Year was the first public recommendation made by David Amsellem?
